BioNTech SE (BNTX) Key Statistics & Financial Ratios

BioNTech SE (BNTX) — Price $96.06 — Healthcare — Biotechnology — NASDAQ

Latest reported results:

Key statistics dashboard for BioNTech SE (BNTX). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.

BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer.

Stock Data

Price$96.06
Market Cap$24.1B
Enterprise Value$11.87B
Beta1.59
ExchangeNASDAQ
CountryDE

Valuation Multiples

P/E Ratio-12.56
Price / Book1.21
P/S8.06
EV/EBITDA-14.19
EV/Sales4.49
EV/FCF22.81
P/FCF40.95
Earnings Yield-7.91%
FCF Yield2.44%
Dividend Yield0.00%

Profitability

Gross Margin68.95%
EBIT Margin-57.35%
EBITDA Margin-31.64%
Operating Margin-64.63%
Net Margin-64.25%
Return on Equity-9.16%
Return on Assets-8.34%
Return on Invested Capital-9.25%
Return on Capital Employed-9.28%

Financial Health

Current Ratio7.85
Quick Ratio7.80
Cash Ratio5.00
Debt / Equity0.02
Debt / Assets1.55%
Net Debt / EBITDA11.28
Interest Coverage-65.51

Per-Share Data

Revenue per share10.44
Book Value per share70.17
Cash per share38.49
FCF per share2.05
Tangible Book Value per share63.08
Dividend per share0.00

Related companies: BIIB · DXCM · GMAB · INCY · NTRA · PHG · RPRX

Explore sector: Healthcare · Biotechnology

More sections of BNTX: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks